Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
Sponsor: Anita Saraf
Summary
The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).
Official title: Efficacy of Sodium Glucose Transporter Inhibitor (SGLT2i) in Adult Patients With Congenital Heart Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-09-17
Completion Date
2027-06-01
Last Updated
2025-10-06
Healthy Volunteers
No
Interventions
Empagliflozin 10 MG
Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year
Placebo
To patients randomized to the placebo group, a placebo pill will be given
Locations (3)
Magee Women's Hospital
Pittsburgh, Pennsylvania, United States
Presbyterian Hospital
Pittsburgh, Pennsylvania, United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States